<DOC>
	<DOC>NCT00414765</DOC>
	<brief_summary>This study will evaluate the pharmacokinetics of aldesleukin in patients with metastatic renal cell cancer and metastatic melanoma</brief_summary>
	<brief_title>Aldesleukin in Patients With Metastatic Renal Cell Carcinoma and Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion criteria: Performance Status Eastern Cooperative Oncology Group: 0 or 1 Adequate organ function Exclusion criteria: Pregnancy or lactation Prior treatment with aldesleukin Organ transplant Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
	<keyword>Aldesleukin</keyword>
	<keyword>IL-2</keyword>
</DOC>